Prescott Group Urges PharmAthene Shareholders to Vote Down Proposed Theraclone Merger

Prescott Group Capital Management, a greater than 10% shareholder of PharmAthene

, urges all stockholders to vote AGAINST the issuance of shares needed to complete the proposed merger with Theraclone Sciences, Inc. and AGAINST giving PharmAthene the right to adjourn the upcoming special meeting. Prescott notes that Institutional Shareholder Services Inc. (ISS), a leading provider of corporate governance solutions, also recommends that PharmAthene stockholders vote AGAINST both of these key proposals. Additionally, Prescott urges shareholders to vote AGAINST all five proposals being submitted to a vote of PharmAthene stockholders at the scheduled December 3rd special meeting. Prescott is not soliciting proxies relating to the meeting and